Results 161 to 170 of about 42,835 (204)

Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case. [PDF]

Cancer Rep (Hoboken)
Mohammadkarimi V, Khalafi-Nezhad A, Najafi B, Alemzadeh N, Ghanbarinasab Z, Vahid R.   +5 more
europepmc   +1 more source

Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. [PDF]

Mediterr J Hematol Infect Dis
Silva N, Duarte G, Medina S, Amarante GD, de Souza CA, Pagnano K.   +5 more
europepmc   +1 more source

Tailored strategies for improved control of CAR-T cells in multiple myeloma. [PDF]

Front Immunol
Bielowski A, Kilian T, Vera-Cruz S, Deveuve Q, Kraus S, Einsele H, Hudecek M, Danhof S.   +7 more
europepmc   +1 more source

Structure-Selective Polydopamine Coating on Drug Nanoparticles. [PDF]

ACS Appl Mater Interfaces
Niezni D, Azagury DM, Avrashami M, Bar-Natan O, Shamay Y.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dasatinib

Reactions Weekly, 2009
Dasatinib is an orally available short-acting dual ABL/SRC tyrosine kinase inhibitor (TKI). It potently inhibits BCR-ABL and SRC family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-α and PDGFR-β, and ephrin receptor kinase. Dasatinib is an effective treatment for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute ...
Markus, Lindauer, Andreas, Hochhaus
  +11 more sources

Dasatinib

Reactions Weekly, 2014
Dasatinib (Sprycel®), a second-generation TKI, has been shown to be effective as an anticancer drug in the treatment of patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib. Several methods of gefitinib synthesis are included in this review.
Hesham M, Korashy, A F M Motiur, Rahman, Mohammed Gabr, Kassem   +2 more
  +5 more sources